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Background: Treatment with carvedilol has been established as a primary therapy in patients with heart failure. However, adverse symptoms or 
signs often discourages continuation or increases in dosage of this medication. We speculated that switching to bisoprolol would help avoid adverse 
symptoms and signs related to carvedilol administration.
Methods: Data were retrospectively collected from 23 patients with heart failure (age 57±18 years, NYHA 2.6±0.7, left ventricular ejection fraction 
(LVEF) 33±15%) who could not increase their dosage of carvedilol (5.60±3.43 mg) because of adverse symptoms (dizziness, syncope) or signs 
(hypotension: systolic blood pressure (SBP) <90 mmHg). Six months after switching to bisoprolol, we checked symptoms, vital signs, laboratory 
data and clinical status (NYHA class). Furthermore, left ventricular (LV) dimension and contraction were evaluated in 17 of 23 patients using 
echocardiography.
Results: All of 13 symptomatic patients (100%) and 5 of 10 asymptomatic patients (50%) were relieved of adverse symptoms or signs. The dose 
of bisoprolol was increased from 1.84±1.08 to 3.13±1.74 mg (p<0.01). At 6-month follow-up examinations, LV function measured by LVEF was 
significantly improved, accompanied by improvement of exercise tolerance.
Conclusions: Switching from carvedilol to bisoprolol may help with continuation of `-blocker treatment as well as dosage increase in patients 
with adverse symptoms or signs, allowing them to reach the target dose.
Parameters Baseline 6months p value
SBP, mmHg 94.1±44.1 109.4±55.1 <0.05
HR, bpm 77.1±38.2 74.6±37.2 NS
NYHA class 2.6±1.2 2.4±1.1 <0.05
Hb, mg/dl 11.6±5.9 12.0±6.2 NS
Cre, mg/dl 1.08±0.66 1.25±0.78 <0.01
BNP, pg/ml 340.8±417.2 374.9±529.5 NS
LVDd, mm 59.8±31.5 58.0±31.5 NS
LVDs, mm 51.4±27.9 46.2±25.7 <0.01
LVEF, % 30.3±18.1 39.4±21.8 <0.001
